Aquestive Therapeutics logo

Aquestive Therapeutics

NYSE:AQSTLive AI agent

Investor website: https://aquestive.com/

About

Aquestive is a pharmaceutical company dedicated to advancing medicines that significantly improve patients' lives through innovative science and delivery technologies. Utilizing proprietary technologies such as PharmFilm® and AdrenaVerse™, the company focuses on developing patient-friendly alternatives to traditional therapies, including investigational treatments for anaphylaxis and alopecia areata. Founded in 2005, Aquestive has built a robust drug delivery platform and has expertise across the entire product lifecycle, from formulation to commercialization, with several FDA-approved products and a commitment to ethical conduct and environmental stewardship.

Verified company data

Cash position
$110.7 million
Shares outstanding
98,871,369
Projects

Anaphylm™ (dibutepinephrine) sublingual film
Potential Indication
Type 1 allergic reactions, including anaphylaxis
Pre-ClinicalPhase 1Phase 2Phase 3
An oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.
Learn more

AQST-108 (epinephrine) topical gel
Potential Indication
(multiple potential indications)
Pre-ClinicalPhase 1Phase 2Phase 3

Libervant® (diazepam) buccal film
Potential Indication
Acute repetitive seizures / cluster seizures
Pre-ClinicalPhase 1Phase 2Phase 3
An oral film formulation of diazepam being developed as a rescue therapy for intermittent, stereotypic episodes of frequent seizure activity (also known as seizure clusters) in patients with epilepsy.
Learn more

Leadership

Daniel Barber (Chief Executive Officer, President and Director, Appointed CEO in May 2022 after serving as COO since May 2019. Joined Aquestive in 2007 and has played a key role in its growth, overseeing the launch of the company's first two FDA approved products.), Kristin Sokol, MD, MS, MPH, FACAAI, FAAAAI (not discovered), Wanda Phipatanakul, MD, MS (not discovered), S. Shahzad Mustafa, MD (not discovered), Douglas P. Mack, MSc, MD, FRCPC, FCSACI (not discovered), Scott Commins, MD, PhD (not discovered), Christina E. Ciaccio, MD, MSc (not discovered), Aikaterini Anagnostou, MD, PhD (not discovered), Rich Daly (not discovered), Thomas A. Zalewski (not discovered), John Oppenheimer, M.D. (not discovered)

Verified data last updated:

Recent filings

Investor FAQ

Answers last refreshed: